



DEPARTMENT OF HEALTH & HUMAN SERVICES

ANDA 77-836

Food and Drug Administration
Rockville MD 20857

JUL 27 2006

InvaGen Pharmaceuticals, Inc.
Attention: Sudhakar R. Vidiyala
President
7 Oser Avenue
Hauppauge, NY 11788

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated August 12, 2005, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Gemfibrozil Tablets USP, 600 mg.

Reference is also made to your amendments dated January 10, March 21, and April 26, 2006.

We have completed the review of this ANDA and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved. The Division of Bioequivalence has determined your Gemfibrozil Tablets USP, 600 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Lopid Tablets, 600 mg, of Pfizer Pharmaceuticals, Ltd. Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.


Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with

applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Robert H. Buehler / for". The signature is fluid and cursive, with a large "R" and "B" at the beginning. A vertical line separates the name from the word "for".

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research